Eleven new medicines have been put forward for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new options for a rare eye disease, schizophrenia and cartilage defects.
European regulators have agreed to review Italian drugmaker Dompe’s orphan drug Oxervate, opening the door to what may potentially become the first biotech treatment available to patients with the more severe forms of an eye condition called neurotrophic keratitis.